

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

{Carton, Label}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Boflox flavour 20 mg tablets for dogs and cats  
Marbofloxacin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains :  
**Active substance:**  
Marbofloxacin 20 mg

**3. PHARMACEUTICAL FORM**

Tablet

**4. PACKAGE SIZE**

10 tablets  
20 tablets  
50 tablets  
100 tablets  
150 tablets  
200 tablets

**5. TARGET SPECIES**

Dog, cat

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

oral use  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

Shelf life of tablet halves and quarters: 4 days  
EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Store in the original container.  
If the tablets are divided, the remaining halves and quarters should be kept in the blister pocket.  
Any divided tablet halves and quarters remaining after 4 days should be discarded.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LIVISTO Int'l, S.L.  
Av. Universitat Autònoma, 29  
08290 Cerdanyola del Vallès  
(Barcelona)  
Spain

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 43173/4004

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

{Blister}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Boflox flavour 20 mg tablets for dogs and cats  
(*target species in form of pictogram*)

Marbofloxacin



**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

LIVISTO Int'l, S.L.

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Batch {number}

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**

Boflox flavour 20 mg tablets for dogs and cats

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

LIVISTO Int'l, S.L.  
Av. Universitat Autònoma, 29  
08290 Cerdanyola del Vallès  
(Barcelona)  
Spain

Manufacturer responsible for batch release:

aniMedica GmbH  
Im Südfeld 9  
48308 Senden-Bösensell  
Germany

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Boflox flavour 20 mg tablets for dogs and cats  
Marbofloxacin

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each tablet contains:

**Active substance:**  
Marbofloxacin 20 mg

Round beige cross-snap tablets with brown speckles.  
The tablets can be divided into halves or quarters.

**4. INDICATION(S)**

Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin.

In dogs:

- skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis)
- urinary tract infections (UTI) associated or not with prostatitis or epididymitis
- respiratory tract infections.

In cats:

- skin and soft tissue infections (wounds, abscesses, phlegmons);
- upper respiratory tract infections.

## **5. CONTRAINDICATIONS**

Marbofloxacin should not be used in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bonvier and Mastiffs, with a longer growth period.

Do not use in cats aged less than 16 weeks.

Do not use in cases of hypersensitivity to fluoroquinolones or any of the excipients of the product.

Do not use in cases of resistance against quinolones, since (almost) complete cross-resistance exists against other fluoroquinolones.

Not suitable for infections resulting from strict anaerobes, yeast or fungi.

## **6. ADVERSE REACTIONS**

At the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats. In particular, no lesions of the articular joints were encountered in clinical studies at the recommended dose rate. However, joint pain and/or neurological symptoms (ataxia, aggressiveness, convulsion, depression) may occur on rare occasions.

Allergic reactions have been observed (temporary skin reactions) due to the histamine release that may occur.

Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

## **7. TARGET SPECIES**

Dog, cat.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For oral administration.



The recommended dose rate is 2 mg/kg/d (1 tablet for 10 kg per day) in single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

The 20mg tablet can be accurately and easily broken into four equal quarters by pressing with the thumb on the top facing score line

Duration of treatment:

Dogs:

In skin and soft tissue infections, treatment duration is at least 5 days. Depending on the course of the disease, it may be extended up to 40 days.

In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease, it may be extended up to 28 days.

In respiratory infections, treatment duration is at least 7 days. Depending on the course of the disease, it may be extended up to 21 days.

Cats:

For skin and soft tissue infections (wounds, abscesses, phlegmons) treatment duration is 3 to 5 days.

For upper respiratory infections, treatment duration is 5 days.

## **9. ADVICE ON CORRECT ADMINISTRATION**

None.

## **10. WITHDRAWAL PERIOD**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Store the blisters in the original container.

If the tablets are divided, the remaining halves and quarters should be kept in the blister pocket.

Any divided tablet halves and quarters remaining after 4 days should be discarded.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after "EXP"

The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

### Special warnings for each target species

A low urinary pH could have an inhibitory effect on the activity of marbofloxacin.

Pyoderma occurs mostly secondary to an underlying disease, thus, it is advisable to determine the underlying cause and treat the animal accordingly.

Special precautions for use in animals:

The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately especially in young animals.

The fluoroquinolones are also known for their potential neurological side effects. Cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may reduce effectiveness of treatment with other quinolones due to the potential for cross-resistance.

Official and local antimicrobial policies should be taken into account when the product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to (fluoro)quinolones should avoid contact with the veterinary medicinal product.

In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use.

Pregnancy/Lactation:

Studies in pregnant rats and rabbits showed no side effects on pregnancy. However no specific studies have been carried out in pregnant dogs and cats.

Use in pregnant and lactating animals should be in accordance with the benefit/risk assessment performed by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron). In such cases, the bioavailability may be reduced.

Do not use in combination with tetracyclines, macrolides because of the potential antagonist effect.

When administered together with theophylline, the half-life and thus the plasma concentration of theophylline increases. Hence, the dose of theophylline should be reduced.

Overdose (symptoms, emergency procedures, antidotes):

Overdosage may cause cartilage damage in the joints and acute signs in the form of neurological disorders (e.g. salivation, streaming eyes, shivering, myoclonia, seizures), which should be treated symptomatically.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

November 2021

**15. OTHER INFORMATION**

Package sizes:

Box with 10 tablets

Box with 20 tablets

Box with 50 tablets


Box with 100 tablets

Box with 150 tablets

Box with 200 tablets.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.



Approved: 23 May 2022